RAAS Modulators: ACE Inhibitors, ARBs, Renin Inhibitors and Mineralocorticoid Antagonists

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance.

Clinical overview

The renin–angiotensin–aldosterone system (RAAS) maintains blood pressure, extracellular volume and potassium homeostasis. Pharmacologic blockade is central to treatment of hypertension, heart failure and albuminuric chronic kidney disease (CKD). These drug families act at different points in the system, and benefit depends on the particular agent and indication [1–3].

Physiology and drug mechanisms

Renin converts angiotensinogen to angiotensin I; ACE converts it to angiotensin II, which stimulates AT1 receptors and aldosterone synthesis. ACE inhibitors (enalapril, lisinopril, ramipril) reduce angiotensin II formation and bradykinin breakdown. ARBs (losartan, valsartan, candesartan) selectively block AT1 signaling. Aliskiren directly inhibits renin. Steroidal mineralocorticoid receptor antagonists (MRAs) include spironolactone and eplerenone; finerenone is a nonsteroidal MRA with outcome evidence in selected type 2 diabetes-associated CKD [1,2].

Evidence-based uses

KDIGO 2024 recommends ACEi or ARB treatment for specific CKD groups with increased albuminuria, especially with diabetes, and using a highest tolerated approved dose when indicated. In eligible adults with type 2 diabetes, CKD, albuminuria despite optimized RAAS inhibition, normal serum potassium and eGFR above 25 mL/min/1.73 m², finerenone can reduce kidney and cardiovascular events. Steroidal MRAs are important in eligible HFrEF and resistant hypertension but require potassium monitoring [2,3].

Dosing, PK and monitoring

ACE inhibitor and ARB elimination varies: lisinopril is chiefly renally eliminated, while losartan undergoes hepatic activation. Spironolactone generates active metabolites, and finerenone is metabolized mainly by CYP3A4. Check blood pressure, creatinine and potassium within 2–4 weeks after starting or increasing ACEi/ARB, sooner in high-risk patients. An initial creatinine rise may be hemodynamic; evaluate a rise exceeding 30%. MRA monitoring frequency is drug- and indication-dependent [1–3].

Adverse effects, contraindications and interactions

ACE inhibitors can cause cough or bradykinin-mediated angioedema. ACEi, ARBs, direct renin inhibitors and MRAs may cause hyperkalemia and hypotension. Do not routinely combine an ACE inhibitor, ARB and/or direct renin inhibitor in CKD: dual blockade increases renal and potassium harms. Renin–angiotensin blockers are contraindicated during pregnancy. NSAIDs, dehydration, potassium supplements and potassium-sparing diuretics can amplify risks. ACE inhibitor switching to or from sacubitril/valsartan requires the prescribed 36-hour washout [1–3].

Clinical pearls

Avoid describing aliskiren as a peptide drug; it is a nonpeptide direct renin inhibitor. Finerenone is not interchangeable with spironolactone for all indications. Effective RAAS care couples an evidence-supported indication with dosing, laboratory monitoring and patient counselling [1–3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Kidney Disease: Improving Global Outcomes. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314. Available from: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf
  3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145:e895–e1032. Available from: https://doi.org/10.1161/CIR.0000000000001063
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *